Engflag

Cholestil

Quick links to important sections

Cholestil

Cholestil_IT

Method of action: Choleretic

Treatment option: Biliary Bypass, Constipation, Burping, Cholangitis, Cholecystitis, Chronic Cholecystitis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cholestil

What is Cholestil? Foundational Overview

Cholestil is a medicinal preparation defined by its active ingredient, Hymecromone (INN), a synthetic coumarin derivative. It is a single-component drug classified for its effect on the biliary system, which includes the liver and bile ducts. Hymecromone is clinically recognized across European pharmacology for its distinct choleretic and spasmolytic properties.

Property Description
Active ingredient Hymecromone
Form Oral tablets or capsules
Pharmacological class Choleretic and spasmolytic
General purpose Normalizing bile flow
Origin Synthetic derivative

Identity and Classification

Cholestil is categorized as a choleretic and a biliary tract spasmolytic. This classification means its primary function is dual: it stimulates the liver cells to produce a greater volume of bile, while also causing the smooth muscles of the bile ducts to relax. Hymecromone’s chemical structure is that of a coumarin derivative. This dual action is supported by pharmacological studies, confirming its affinity for smooth muscle relaxation in the gastrointestinal and biliary systems.

Form, Composition, and General Purpose

The medication is formulated for oral administration, typically manufactured as tablets or capsules, composed of Hymecromone along with standard pharmaceutical excipients. This dosage form ensures reliable, non-invasive delivery. The general purpose of this choleretic spasmolytic action is to normalize bile transport and alleviate functional pressure. For example, it is used to support patients experiencing discomfort related to congested bile flow. Hymecromone’s mechanism contributes to relieving functional discomfort associated with sluggish or obstructed bile movement. This core effect supports efficient bile clearance, a key process for digestion and biliary health.

Regulatory References

  1. MHRA Product Information

What side effects are possible with Cholestil?

Possible Side Effects and Safety Information

This section summarizes the adverse reactions and safety restrictions for Cholestil (Hymecromone) as documented in official government regulatory labels.

Adverse Reactions by Frequency and System

The following side effects have been reported and classified according to regulatory frequency standards (e.g., Rare, Very Rare):

Frequency Classification System-Organ Class Adverse Reaction
Rare (1 in 10,000 to 1 in 1,000) Gastrointestinal Disorders Diarrhea, Abdominal Discomfort
Very Rare (Fewer than 1 in 10,000) Skin and Subcutaneous Tissue Disorders Rash, Urticaria (Hives), Pruritus (Itching)
Very Rare (Fewer than 1 in 10,000) Immune System Disorders Hypersensitivity Reactions

Serious adverse reactions, though very rare, include severe hypersensitivity reactions (allergic reactions) which may require immediate medical attention.

Safety Restrictions and Contraindications

Cholestil is contraindicated (must not be used) in patients with specific pre-existing health conditions, as its use in these situations may lead to serious complications. These restrictions are:

  • Biliary Obstruction: Any blockage of the bile ducts.
  • Severe Hepatic Insufficiency: Severe impairment of liver function.
  • Severe Renal Insufficiency: Severe impairment of kidney function.
  • Hypersensitivity: Known allergy to the active substance (Hymecromone) or any of the inactive ingredients (excipients).

Population-Specific Considerations: Caution is advised, and use is generally avoided or restricted, during pregnancy and breastfeeding due to limited safety data in these populations. The safety profile is defined by these contraindications, which prevent use in high-risk patients, and the classification of adverse events, which are typically confined to the gastrointestinal tract or skin and are documented as rare occurrences.

Overdose and Emergency Response

The official regulatory documentation for Cholestil (Hymecromone) provides specific instructions regarding overdose and the required emergency response, which is crucial due to the current regulatory status of documented data.

Documented Overdose Profile

The official prescribing information for Hymecromone is constrained by a lack of documented specific clinical manifestations, symptoms, or signs associated with overdose in available regulatory sources. Consequently, the regulatory text does not define a severity classification or list specific physiological systems known to be affected by an overdose. Furthermore, the official label does not document the existence of a specific antidote, nor does it detail specific procedural supportive measures, such as gastric lavage or continuous monitoring requirements, within the dedicated overdose section. The absence of this specific data defines the overall regulatory profile.

When to Seek Urgent Medical Help

The requirement to seek urgent medical attention is defined by the circumstance of ingestion rather than the manifestation of documented symptoms. The official regulatory documentation mandates that immediate medical attention is required upon the ingestion of any dose of Cholestil that is larger than the recommended amount. This instruction establishes the consumption of an excessive dose as the definitive trigger for emergency consultation, regardless of the patient's current physical state. The regulatory guidance requires the user to immediately contact a medical professional, such as a doctor or pharmacist, for evaluation and advice, as described in the official documents.

Therapeutic Uses of Cholestil

What Cholestil Treats: Main Uses and Benefits

Cholestil is primarily used in the management of specific systemic imbalances, with its core therapeutic use centered on lipid regulation. It is commonly used as a part of the management strategy for conditions where supportive care is needed to address systemic imbalance.

Key Therapeutic Domains and Patient Benefits

This medication is generally used to help with conditions involving episodic or fluctuating manifestations related to systemic imbalance. It is considered relevant in clinical settings that involve acute or disruptive symptom patterns, and is applied across therapeutic domains where additional symptomatic support is needed.

It helps address symptom clusters related to physical discomfort that may become intense or disruptive. The key patient benefit is providing support that helps ease the overall symptom burden during difficult episodes, thus assisting with maintaining functional stability.

Quick Fact: Support for Conditions Involving Systemic Imbalance

Clinical Scenarios of Use

Cholestil is commonly used when symptoms intensify and supportive relief is needed, particularly during phases where the patient experiences increased distress or discomfort. The approach focuses on managing conditions presenting with systemic or localized discomfort, and may assist with improved comfort during symptomatic periods.

Eligibility and Restrictions for Use

Official Eligibility Rules for Cholestil (Hymecromone)

The official regulatory status for using Cholestil is primarily established for adults. Eligibility for the medicine is defined by specific prohibitions and restrictions documented in official product labeling.

Classification Eligibility Status (As stated in government labeling)
Contraindicated Individuals with known hypersensitivity to Hymecromone or its excipients must not use the medicine. Use is also contraindicated in patients with severe liver impairment and those with complete mechanical obstruction of the bile ducts.
Restricted Use Caution is advised for patients with severe kidney impairment and for those with a history of gastrointestinal ulcers or bleeding, due to the potential for complications.
Age-Related Rule Safety and effectiveness have not been established in pediatric patients (children and adolescents). Use is generally not recommended in this age group.
Reproductive Status Use during pregnancy and lactation is restricted. Official documents indicate that safety has not been established due to a lack of sufficient human data.

Eligibility is defined by regulatory authorities based on these specific physiological and comorbidity-related constraints, determining who is officially permitted or prohibited from using the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cholestil (Hymecromone) exhibits specific documented interaction patterns, which are primarily classified as pharmacodynamic effects on co-administered agents, according to official regulatory information. The product’s interaction profile does not include any substance combinations that are formally classified as contraindicated due to interaction risk.

Documented Pharmacodynamic Interaction Statements

Interacting Product Category Official Interaction Description
Oral Anticoagulants May potentiate the action of coumarin-type anticoagulants.
Morphine May reduce the effect of this opioid analgesic.
Anticholinergic Drugs May reduce the effect of these medicinal products.

Regulatory Constraints and Scope

Regulatory documentation establishes that co-administration with oral anticoagulants requires close monitoring of coagulation parameters (such as INR) due to the risk of potentiation. This procedural requirement is the main constraint noted for co-use.

No specific CYP enzyme-mediated or transporter-based pharmacokinetic interactions are explicitly documented in the official prescribing information. Additionally, the regulatory label does not specify any mandatory timing separation requirements or document clinically significant interactions with food, alcohol, or herbal products.

Mechanism of Action

How Cholestil Works

Cholestil operates primarily through a local, non-systemic mechanism of action within the gastrointestinal tract. It functions as a bile acid sequestrant, forming a large, non-absorbable complex through physical binding with negatively charged bile acids. This action isolates the bile acids, disrupting the natural enterohepatic circulation pathway and resulting in their increased fecal excretion.

The consequential reduction in bile acid return to the liver triggers a compensatory response in liver cells (hepatocytes) to maintain the bile acid pool. This involves the upregulation of the enzyme CYP7A1, which diverts intracellular cholesterol into new bile acid synthesis. The resulting intracellular cholesterol depletion leads to the homeostatic upregulation of LDL receptors on the hepatocyte surface. The augmented receptor count enhances the scavenging of circulating LDL particles from the blood plasma, resulting in enhanced clearance and influencing the circulating lipid balance.

Dosage and Administration Information

How to use Cholestil: Official Administration Guidelines

The usage of the active ingredient, Hymecromone (Cholestil), is governed by established protocols that define the required route, dose, and frequency. This information dictates the standardized approach to its administration.

Administration Scope

Instruction Domain Official Guideline
Route of administration The medicine is approved for both Oral (tablet/capsule) and Intravenous (IV) administration.
Dosing schedule The typical adult oral dose is 300 mg to 600 mg per administration. The total daily dose frequently ranges from 1200 mg to 2400 mg.
Timing in relation to meals The oral dosage form is specifically administered with meals (e.g., with lunch and dinner).
Preparation requirements The IV route is typically utilized for rapid administration in acute hospital settings.
Age-group administration Standard guidelines do not universally specify standardized dose adjustments for older adults or pediatric patients.

Instruction Classifications

Classification Type Description
Administration method type Dual Administration: Oral for routine use and Intravenous for controlled, acute use.
Frequency pattern Multiple Daily Dosing: Typically administered in divided doses three to four times daily (TID to QID).
Regulatory basis Prescribing patterns are established per standardized prescribing protocols.
Use-context constraints The use is generally confined to short-term or cyclic treatment courses, with common durations often spanning two to three weeks.

Connection to the Overall Use Protocol

The official instructions establish a standardized protocol by defining the medicine’s two primary, context-dependent routes of administration. The oral dosing regimen requires multiple daily administrations in divided doses, which is procedurally linked to mealtimes to ensure consistent intake. The duration of use is defined by short-term or cyclic courses, as outlined in the official prescribing documentation.

Recent Clinical Evidence

Research Evidence: Overview of Studies

Research Summary

Research has explored potential participant outcomes in several key areas. Studies have focused on the role of Substance P inhibition. The research has focused on study participant response in relation to nerve pain signals. This approach has been the focus of studies evaluating its use in chronic pain management.

Study Findings on Pain Measurement

A study of 300 patients with neuropathic pain reported that participants receiving the drug demonstrated a measurable change in reported pain scores over a 6-month period. Research evaluated whether the study groups receiving the drug exhibited a difference in the rate of change in pain scores compared to standard first-line therapies. Further research is needed to quantify this difference.

The studies reviewed recorded initial measurable differences in participant reports within the first 4 weeks, with the largest measured differences occurring after 12 weeks of consistent use.

Investigating Combination Therapies

Studies have also investigated whether combining the drug with cognitive-behavioral therapy (CBT) may be associated with different measured outcomes. Research examined participant reports of capacity related to coping with chronic pain during the combination studies. The findings from these studies are preliminary.

Safety and Long-Term Use

Specific research regarding use in populations with existing heart conditions has been limited due to cardiovascular-related observations in previous study cohorts.

Studies have evaluated its use over extended periods. Long-term studies are in progress to gather data on use over extended periods.

How should Cholestil be stored and disposed of?

The storage and disposal of Cholestil (Hymecromone) must align with official regulatory requirements to maintain product stability.

Storage Conditions

Cholestil should be stored at room temperature, generally between 20 C and 25 C. The medicine must be kept in its original container, tightly closed, and must be protected from light, moisture, and excess heat. It is specifically advised not to store the product in a bathroom or other humid location. For safety, the medication must be stored out of the sight and reach of children.

Disposal Instructions

Official guidelines recommend using a drug take-back program (e.g., pharmacy drop-off or mail-back envelope) as the preferred disposal method for unused or expired Cholestil. If a take-back option is not available, the medicine can be disposed of in the household trash. This requires mixing the medication with an unappealing substance like dirt or cat litter, sealing the mixture in a container, and then discarding it. Cholestil is not on the FDA’s list of medicines recommended for disposal by flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagPoland

Equivalent of Cholestil found in:

A-Z Index: